MA56001A - Formes de sel cristallin d'un inhibiteur de kinase - Google Patents

Formes de sel cristallin d'un inhibiteur de kinase

Info

Publication number
MA56001A
MA56001A MA056001A MA56001A MA56001A MA 56001 A MA56001 A MA 56001A MA 056001 A MA056001 A MA 056001A MA 56001 A MA56001 A MA 56001A MA 56001 A MA56001 A MA 56001A
Authority
MA
Morocco
Prior art keywords
kinase inhibitor
salt forms
crystalline salt
crystalline
forms
Prior art date
Application number
MA056001A
Other languages
English (en)
Inventor
Melanie Janelle Bevill
Frenel Demorin
Courtney S Johnson
Stephan D Parent
Khalid Shah
Sagar Shakya
Peter Wong
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA56001A publication Critical patent/MA56001A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA056001A 2019-06-03 2019-12-12 Formes de sel cristallin d'un inhibiteur de kinase MA56001A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03

Publications (1)

Publication Number Publication Date
MA56001A true MA56001A (fr) 2022-04-06

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056001A MA56001A (fr) 2019-06-03 2019-12-12 Formes de sel cristallin d'un inhibiteur de kinase

Country Status (19)

Country Link
US (1) US20230052703A1 (fr)
EP (1) EP3976587A1 (fr)
JP (1) JP2022535072A (fr)
KR (1) KR20220016117A (fr)
CN (1) CN113939503B (fr)
AU (1) AU2019449809A1 (fr)
BR (1) BR112021024300A2 (fr)
CA (1) CA3139148A1 (fr)
CL (1) CL2021003205A1 (fr)
CO (1) CO2021017343A2 (fr)
CR (1) CR20210616A (fr)
DO (1) DOP2021000236A (fr)
GE (1) GEP20247655B (fr)
IL (1) IL288484A (fr)
MA (1) MA56001A (fr)
MX (1) MX2021014773A (fr)
PE (1) PE20220962A1 (fr)
SG (1) SG11202111978VA (fr)
WO (1) WO2020247019A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3088200A1 (fr) * 2018-01-26 2019-08-01 Exelixis, Inc. Composes destines au traitement de troubles dependant de la kinase
GEP20247596B (en) * 2018-12-13 2024-02-26 Exelixis Inc A Delaware Corp Crystalline forms and salt forms of a kinase inhibitor
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
CN118647603A (zh) 2021-12-22 2024-09-13 埃克塞里艾克西斯公司 激酶抑制剂的结晶形式和盐形式

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2925655T3 (es) * 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
EP1871417B1 (fr) 2005-04-15 2013-09-11 Precision Biologics, Inc. Anticorps monoclonaux recombinés et antigènes correspondants contre les cancers du colon et du pancréas
CA3139031A1 (fr) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
CA2910278C (fr) 2013-05-02 2021-09-28 Anaptysbio, Inc. Anticorps diriges contre la proteine de mort programmee 1 (pd-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
WO2018218233A1 (fr) * 2017-05-26 2018-11-29 Exelixis, Inc. Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
CA3088200A1 (fr) 2018-01-26 2019-08-01 Exelixis, Inc. Composes destines au traitement de troubles dependant de la kinase
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
CN113939503B (zh) 2024-05-07
WO2020247019A1 (fr) 2020-12-10
SG11202111978VA (en) 2021-11-29
AU2019449809A1 (en) 2021-12-16
CO2021017343A2 (es) 2022-01-17
MX2021014773A (es) 2022-01-18
CL2021003205A1 (es) 2022-09-30
CR20210616A (es) 2022-03-22
JP2022535072A (ja) 2022-08-04
IL288484A (en) 2022-01-01
GEP20247655B (en) 2024-08-26
KR20220016117A (ko) 2022-02-08
EP3976587A1 (fr) 2022-04-06
PE20220962A1 (es) 2022-06-10
BR112021024300A2 (pt) 2022-01-11
DOP2021000236A (es) 2022-04-18
US20230052703A1 (en) 2023-02-16
CA3139148A1 (fr) 2020-12-10
CN113939503A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
MA52493A (fr) Sels d'un inhibiteur de fgfr
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
MA55614A (fr) Formes cristallines d'inhibiteur de pyridazinone trpc
MA42606A (fr) Sels d'un inhibiteur de lsd1
IL290508A (en) Heterocyclic compounds as kinase inhibitors
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
IL289929A (en) Crystal forms of cd73 inhibitor
IL287668A (en) Crystalline forms of btk inhibitor
MA54638A (fr) Formes cristallines d'un stimulateur de sgc
IL289389A (en) Heterocyclic compounds as kinase inhibitors
PL3826982T3 (pl) Zastosowanie podstawionych związków tiazolidynowych jako inhibitora nitryfikacji
MA54087A (fr) Sels cristallins d'un inhibiteur de la kallicréine plasmatique
ZA202109183B (en) Novel compounds for inhibition of janus kinase 1
IL284226A (en) Crystal structures of a TGFB inhibitor
MA53671A (fr) Formes cristallines d'un agoniste du récepteur farnésoïde x
SG11202102110PA (en) Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor
IL281168A (en) Crystal forms of the quinazole compound and its hydrochloride salts
MA54689A (fr) Formes cristallines de 1-(1,2-diméthylpropyl)-n-éthyl-5-méthyl-n-pyridazin-4-yl-pyrazole-4-carboxamide
PL3891156T3 (pl) Nowe krystaliczne formy inhibitora MCL-1, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
IL285427A (en) Crystal forms of jak2 inhibitor
MA53561A (fr) Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k)
IL279953A (en) Crystal forms of LTA4H inhibitor
MA53162A (fr) Sel de xinafoate d'un composé inhibiteur de jak